Plasmatherapy in atypical hemolytic uremic syndrome

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 6, 2010, Pages 673-681

  Loirat, Chantal ^a   Garnier, Arnaud ^a   Sellier Leclerc, Anne Laure ^a   Kwon, Theresa ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Atypical hemolytic uremic syndrome; complement; plasma exchange; plasma infusions

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT INHIBITOR; CREATININE; FIBRINOGEN; FRESH FROZEN PLASMA; MEMBRANE COFACTOR PROTEIN; RECOMBINANT THROMBOMODULIN; THROMBOMODULIN;

BLOOD TRANSFUSION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; GENE MUTATION; GENETIC ANALYSIS; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; PLASMA VOLUME; PLASMAPHERESIS; PLASMATHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RELAPSE; REMISSION; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIGENS, CD46; COMPLEMENT FACTOR H; FIBRINOGEN; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY FAILURE, CHRONIC; MUTATION; PLASMA EXCHANGE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957564292     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1262890     Document Type: Review

References (59)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009 361 (17) 1676-1687
2. Caprioli J, Noris M, Brioschi S et al, International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006 108 (4) 1267-1279
3. Sellier-Leclerc A L., Freméaux-Bacchi V, Dragon-Durey M A. et al, French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007 18 (8) 2392-2400
4. Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008 23 (11) 1957-1972
5. Byrnes J J., Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977 297 (25) 1386-1389
6. Bukowski R M., King J W., Hewlett J S. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977 50 (3) 413-417
7. Bell W R., Braine H G., Ness P M., Kickler T S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991 325 (6) 398-403
8. Rock G A., Shumak K H., Buskard N A. et al, Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991 325 (6) 393-397
9. Rizzoni G, Claris-Appiani A, Edefonti A et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988 112 (2) 284-290
10. Loirat C, Sonsino E, Hinglais N, Jais J P., Landais P, Fermanian J, The French Society of Paediatric Nephrology. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. Pediatr Nephrol 1988 2 (3) 279-285
11. Michael M, Elliott E J., Craig J C., Ridley G, Hodson E M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009 53 (2) 259-272
12. Noris M, Remuzzi G. Thrombotic microangiopathy: what not to learn from a meta-analysis. Nat Rev Nephrol 2009 5 (4) 186-188
13. Gianviti A, Perna A, Caringella A et al. Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis 1993 22 (2) 264-266
14. Ruggenenti P, Remuzzi G. Pathophysiology and management of thrombotic microangiopathies. J Nephrol 1998 11 (6) 300-310
15. Eddy A A., Geary D F., Balfe J W., Clark W F., Baumal R. Prolongation of acute renal failure in two patients with hemolytic-uremic syndrome due to excessive plasma infusion therapy. Pediatr Nephrol 1989 3 (4) 420-423
16. Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship T H. Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr Nephrol 2004 19 (8) 908-911
17. Saunders R E., Abarrategui-Garrido C, Frémeaux-Bacchi V et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 2007 28 (3) 222-234
18. Pichette V, Quérin S, Schrch W, Brun G, Lehner-Netsch G, Delge J M. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994 24 (6) 936-941
19. Ohali M, Shalev H, Schlesinger M et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 1998 12 (8) 619-624
20. Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001 138 (3) 412-417
21. Nathanson S, Frémeaux-Bacchi V, Deschěnes G. Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 2001 16 (7) 554-556
22. Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschěnes G. Secondary failure of plasma therapy in factor H deficiency. Pediatr Nephrol 2006 21 (11) 1769-1771
23. Licht C, Weyersberg A, Heinen S et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005 45 (2) 415-421
24. Cho H Y., Lee B S., Moon K C., Ha I S., Cheong H I., Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007 22 (6) 874-880
25. Sethi S K., Marie-Agnes D D., Thaker N, Hari P, Bagga A. Hemolytic uremic syndrome due to homozygous factor H deficiency. Clin Exp Nephrol 2009 13 (5) 526-530
26. Larakeb A, Leroy S, Frémeaux-Bacchi V et al. Ocular involvement in hemolytic uremic syndrome due to factor H deficiencyare there therapeutic consequences? Pediatr Nephrol 2007 22 (11) 1967-1970
27. Stratton J D., Warwicker P. Successful treatment of factor H-related haemolytic uraemic syndrome. Nephrol Dial Transplant 2002 17 (4) 684-685
28. Gerber A, Kirchhoff-Moradpour A H., Obieglo S et al. Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality. Pediatr Nephrol 2003 18 (9) 952-955
29. Davin J C., Strain L, Goodship T HJ. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008 23 (9) 1517-1521
30. Lapeyraque A L., Wagner E, Phan V et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008 23 (8) 1363-1366
31. Abarrategui-Garrido C, Melgosa M, Pea-Carrin A et al. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008 52 (1) 171-180
32. De S, Waters A M., Segal A O., Trautmann A, Harvey E A., Licht C. Severe atypical HUS caused by CFH S1191Lcase presentation and review of treatment options. Pediatr Nephrol 2010 25 (1) 97-104
33. Ferreira V P., Herbert A P., Cortés C et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009 182 (11) 7009-7018
34. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009 361 (4) 345-357
35. Richards A, Kemp E J., Liszewski M K. et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003 100 (22) 12966-12971
36. Noris M, Brioschi S, Caprioli J et al, International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003 362 (9395) 1542-1547
37. Freméaux-Bacchi V, Moulton E A., Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006 17 (7) 2017-2025
38. Fang C J., Frémeaux-Bacchi V, Liszewski M K. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008 111 (2) 624-632
39. Couzi L, Contin-Bordes C, Marliot F et al. Inherited deficiency of membrane cofactor protein expression and varying manifestations of recurrent atypical hemolytic uremic syndrome in a sibling pair. Am J Kidney Dis 2008 52 (2) e5-e9
40. Davin J C., Buter N, Groothoff J et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009 24 (9) 1757-1760
41. Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007 5 (1) 31-41
42. Frémeaux-Bacchi V, Dragon-Durey M A., Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004 41 (6) e84
43. Bienaimé F, Dragon-Durey M A., Regnier C H. et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010 77 (4) 339-349
44. Kavanagh D, Kemp E J., Mayland E et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005 16 (7) 2150-2155
45. Nilsson S C., Karpman D, Vaziri-Sani F et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 2007 44 (8) 1835-1844
46. Frémeaux-Bacchi V, Miller E C., Liszewski M K. et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008 112 (13) 4948-4952
47. Goicoechea de Jorge E, Harris C L., Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007 104 (1) 240-245
48. Roumenina L T., Jablonski M, Hue C et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009 114 (13) 2837-2845
49. Lhotta K, Janecke A R., Scheiring J et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 2009 4 (8) 1356-1362
50. Ariceta G, Besbas N, Johnson S et al, European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009 24 (4) 687-696
51. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001 60 (3) 831-846 (Pubitemid 34205784)
52. Allford S L., Hunt B J., Rose P, Machin S J., Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003 120 (4) 556-573
53. Taylor C M., Machin S, Wigmore S J., Goodship T H., working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010 148 (1) 37-47
54. Michon B, Moghrabi A, Winikoff R et al. Complications of apheresis in children. Transfusion 2007 47 (10) 1837-1842
55. Witt V, Stegmayr B, Ptak J et al. World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus Apheresis Sci 2008 39 (3) 255-260
56. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009 9 (11) 2644-2645
57. Davin J C., Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010 55 (4) 708-711
58. Nrnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009 360 (5) 542-544
59. Gruppo R A., Rother R P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009 360 (5) 544-546